Literature DB >> 21270637

Evidence for the toxicity of bidirectional transcripts and mitochondrial dysfunction in blood associated with small CGG expansions in the FMR1 gene in patients with parkinsonism.

Danuta Z Loesch1, David E Godler, Andrew Evans, Quang M Bui, Freya Gehling, Katya E Kotschet, Nicholas Trost, Elsdon Storey, Paige Stimpson, Glynda Kinsella, David Francis, David R Thorburn, Alison Venn, Howard R Slater, Malcolm Horne.   

Abstract

PURPOSE: Our previous results showed that both gray zone and lower end premutation range (40-85 repeats) fragile X mental retardation 1 (FMR1) alleles were more common among males with parkinsonism than in the general population. This study aimed to determine whether these alleles have a significant role in the manifestations and pathogenesis of parkinsonian disorders.
METHODS: Detailed clinical assessment and genetic testing were performed in 14 male carriers of premutation and gray zone FMR1 alleles and in 24 noncarriers identified in a sample of males with parkinsonism.
RESULTS: The premutation + gray zone carriers presented with more severe symptoms than disease controls matched for age, diagnosis, disease duration, and treatment. The Parkinson disease (Unified Parkinson's Disease Rating Scale) motor score and the measures of cognitive decline (Mini-Mental State Examination and/or Addenbrooke's Cognitive Examination Final Revised Version A scores) were significantly correlated with the size of the CGG repeat and the (elevated) levels of antisense FMR1 and Cytochrome C1 mRNAs in blood leukocytes. In addition, the carriers showed a significant depletion of the nicotinamide adenine dinucleotide, reduced dehydrogenase subunit 1 mitochondrial gene in whole blood.
CONCLUSION: Small CGG expansion FMR1 alleles (gray zone and lower end premutation) play a significant role in the development of the parkinsonian phenotype, possibly through the cytotoxic effect of elevated sense and/or antisense FMR1 transcripts involving mitochondrial dysfunction and leading to progressive neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21270637      PMCID: PMC4022481          DOI: 10.1097/GIM.0b013e3182064362

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  45 in total

Review 1.  Screening for fragile X syndrome: a literature review and modelling study.

Authors:  F J Song; P Barton; V Sleightholme; G L Yao; A Fry-Smith
Journal:  Health Technol Assess       Date:  2003       Impact factor: 4.014

Review 2.  Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems.

Authors:  S A Bustin
Journal:  J Mol Endocrinol       Date:  2002-08       Impact factor: 5.098

3.  Fragile X premutation alleles in SCA, ET, and parkinsonism in an Asian cohort.

Authors:  E K Tan; Y Zhao; K Y Puong; H Y Law; L L Chan; K Yew; C Tan; H Shen; V R Chandran; M L Teoh; Y Yih; R Pavanni; M C Wong; I S Ng
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

Review 4.  Gene-environment interactions in sporadic Parkinson's disease.

Authors:  Liat Benmoyal-Segal; Hermona Soreq
Journal:  J Neurochem       Date:  2006-06       Impact factor: 5.372

Review 5.  Triplet repeats, RNA secondary structure and toxic gain-of-function models for pathogenesis.

Authors:  R Galvão; L Mendes-Soares; J Câmara; I Jaco; M Carmo-Fonseca
Journal:  Brain Res Bull       Date:  2001 Oct-Nov 1       Impact factor: 4.077

6.  Tremor/ataxia syndrome and fragile X premutation: diagnostic caveats.

Authors:  D Z Loesch; L Litewka; A Churchyard; E Gould; F Tassone; M Cook
Journal:  J Clin Neurosci       Date:  2006-12-27       Impact factor: 1.961

7.  Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination.

Authors:  M Richards; K Marder; L Cote; R Mayeux
Journal:  Mov Disord       Date:  1994-01       Impact factor: 10.338

8.  Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates.

Authors:  Sébastien Jacquemont; Randi J Hagerman; Maureen Leehey; Jim Grigsby; Lin Zhang; James A Brunberg; Claudia Greco; Vincent Des Portes; Tristan Jardini; Richard Levine; Elizabeth Berry-Kravis; W Ted Brown; Stephane Schaeffer; John Kissel; Flora Tassone; Paul J Hagerman
Journal:  Am J Hum Genet       Date:  2003-03-12       Impact factor: 11.025

9.  Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease.

Authors:  R H Haas; F Nasirian; K Nakano; D Ward; M Pay; R Hill; C W Shults
Journal:  Ann Neurol       Date:  1995-06       Impact factor: 10.422

10.  Molecular dissection of the events leading to inactivation of the FMR1 gene.

Authors:  Roberta Pietrobono; Elisabetta Tabolacci; Francesca Zalfa; Ilaria Zito; Alessandra Terracciano; Umberto Moscato; Claudia Bagni; Ben Oostra; Pietro Chiurazzi; Giovanni Neri
Journal:  Hum Mol Genet       Date:  2004-11-24       Impact factor: 6.150

View more
  32 in total

Review 1.  Neurodegeneration the RNA way.

Authors:  Abigail J Renoux; Peter K Todd
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

Review 2.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

3.  Evidence for the role of FMR1 gray zone alleles as a risk factor for parkinsonism in females.

Authors:  Danuta Z Loesch; Flora Tassone; George D Mellick; Malcolm Horne; Justin P Rubio; Minh Q Bui; David Francis; Elsdon Storey
Journal:  Mov Disord       Date:  2018-07       Impact factor: 10.338

4.  Parkinsonism in fragile X-associated tremor/ataxia syndrome (FXTAS): revisited.

Authors:  Yu-Qiong Niu; Jin-Chen Yang; Deborah A Hall; Maureen A Leehey; Flora Tassone; John M Olichney; Randi J Hagerman; Lin Zhang
Journal:  Parkinsonism Relat Disord       Date:  2014-01-18       Impact factor: 4.891

5.  Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions.

Authors:  Lillian M Zwemer; Sarah L Nolin; Patricia M Okamoto; Marcia Eisenberg; Heather C Wick; Diana W Bianchi
Journal:  Prenat Diagn       Date:  2016-10-25       Impact factor: 3.050

Review 6.  Fragile X-associated tremor/ataxia syndrome.

Authors:  Paul J Hagerman; Randi J Hagerman
Journal:  Ann N Y Acad Sci       Date:  2015-01-26       Impact factor: 5.691

7.  Screening for intermediate CGG alleles of FMR1 gene in male Iranian patients with Parkinsonism.

Authors:  Atefeh Entezari; Mahmoud Shekari Khaniani; Tayyeb Bahrami; Sima Mansoori Derakhshan; Hossein Darvish
Journal:  Neurol Sci       Date:  2016-10-01       Impact factor: 3.307

Review 8.  Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management.

Authors:  Randi J Hagerman; Paul Hagerman
Journal:  Nat Rev Neurol       Date:  2016-06-24       Impact factor: 42.937

9.  Neurological and endocrine phenotypes of fragile X carrier women.

Authors:  D Hall; K Todorova-Koteva; S Pandya; B Bernard; B Ouyang; M Walsh; T Pounardjian; C Deburghraeve; L Zhou; M Losh; M Leehey; E Berry-Kravis
Journal:  Clin Genet       Date:  2015-09-04       Impact factor: 4.438

10.  Fragile X-associated tremor/ataxia syndrome (FXTAS) in grey zone carriers.

Authors:  Y Liu; T I Winarni; L Zhang; F Tassone; R J Hagerman
Journal:  Clin Genet       Date:  2012-10-17       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.